Triton (via Triley Bidco) Acquires Clinigen

January 17, 2022

Triton, through a newly-formed acquisition vehicle Triley Bidco Limited, completed an all-cash recommended offer to acquire Clinigen for 925 pence per share. Triton said it will support Clinigen’s next growth phase by extending geographic reach, pursuing inorganic growth opportunities and strengthening Clinigen’s services and digital platform.

Buyers
Triley Bidco Limited (indirectly owned by the Triton Funds), Triton (Triton Funds / Triton Partners)
Targets
Clinigen
Industry
Pharmaceuticals
Location
England, United Kingdom
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.